Jerry L. Nadler, M.D., MACP, FAHA, FACE, served as the dean of the School of Medicine from 2019 to 2023. Born and raised in Brooklyn, New York, Dr. Nadler received a B.A. in Biology and Chemistry from The State University of New York, Binghamton, and his M.D., from the University of Miami’s Miller School of Medicine, where he worked with Dr. Daniel Mintz, the founding scientific director and chief academic officer of the Diabetes Research Institute. He completed his internship and residency in internal medicine at Loma Linda University and completed a three-year clinical and research fellowship in endocrinology and diabetes at the University of Southern California (USC) Los Angeles County Medical Center.
He then received additional research training in cardiovascular disease linked to diabetes, funded by a post-doctoral fellowship sponsored by the American Heart Association. He remained as a tenured faculty in the Endocrine Division at USC. His quest to advance the understanding of diabetes led him to the City of Hope Medical Center in Duarte, California, where he helped to build the City of Hope’s Diabetes Program as its director. Dr. Nadler then moved to Virginia to serve as chief of endocrinology and metabolism at the University of Virginia, co-director of the Diabetes and Hormone Center of Excellence and associate director of the school’s National Institutes of Health (NIH) funded Diabetes Endocrinology Research Center.
Just prior to coming to New York Medical College in 2019, Dr. Nadler served as professor and chair of internal medicine, the Harry H. Mansbach Endowed Chair in Internal Medicine and vice dean of research and director of the Strelitz Diabetes Center (SDC) at Eastern Virginia Medical School (EVMS).
An internationally recognized diabetes researcher, Dr. Nadler has been a member of a Special Advisory Committee on Type I Diabetes with the director of the NIH. In addition, he had been a standing member of the American Diabetes Association, American Heart Association and NIH grant review committees. In 2011, he won the Dean’s Outstanding Faculty Award at EVMS, and in 2013, he was appointed by the Governor’s office of the Commonwealth of Virginia to sit on the Planning and Oversight Committee of the new Virginia Biosciences Health Research Corporation. Based on his excellence in research, he was elected to the American Society of Clinical Investigation.
Dr. Nadler’s groundbreaking contributions—which focus on understanding cardiovascular complications of diabetes and obesity—include his work in identifying inflammatory pathways leading to pancreatic beta cell damage, insulin resistance and atherosclerosis. Toward this end, his research has led to the development of preventative therapies and the identification of new small molecules blocking 12-Lipoxygenase activity. He has research funding from the NIH as well as the Juvenile Diabetes Foundation and his current work is designed to determine whether a virus could be a trigger for Type 1 diabetes.
As a prominent voice in his field, he has authored more than 200 peer-reviewed publications and has been an invited speaker at major international conferences, including the American Diabetes Association, Australian Diabetes Association, World Diabetes Congress and International Meetings of the European Association of Diabetes.
Additionally, as a leader in biomedical innovation, Dr. Nadler holds a number of patents for biomarkers and novel therapeutics. His clinical interest is focused on treatment and prevention of diabetes and related complications.